Preemptive InOtuzumab Ozogamicin eradicated measurable residual disease
in Ph-negative acute lymphoblastic leukemia relapsed post CD19 CART
therapy
- Si-Man Huang
, - Chao-Ling Wan,
- Hanyu Cao,
- Yan-Yan Li,
- Chongsheng Qian,
- Haixia Zhou,
- Mingzhu Xu,
- Xiaohui Hu,
- Lan Dai,
- Hai-Ping Dai,
- Sheng-Li Xue
Si-Man Huang
First Affiliated Hospital of Soochow University
Author ProfileChao-Ling Wan
First Affiliated Hospital of Soochow University
Author ProfileHanyu Cao
First Affiliated Hospital of Soochow University
Author ProfileYan-Yan Li
First Affiliated Hospital of Soochow University
Author ProfileChongsheng Qian
First Affiliated Hospital of Soochow University
Author ProfileHaixia Zhou
First Affiliated Hospital of Soochow University
Author ProfileMingzhu Xu
First Affiliated Hospital of Soochow University
Author ProfileXiaohui Hu
First Affiliated Hospital of Soochow University
Author ProfileHai-Ping Dai
First Affiliated Hospital of Soochow University
Author Profile07 Nov 2023Submitted to Clinical Case Reports 07 Nov 2023Submission Checks Completed
07 Nov 2023Assigned to Editor
07 Nov 2023Reviewer(s) Assigned
07 Nov 2023Reviewer(s) Assigned
16 Nov 2023Review(s) Completed, Editorial Evaluation Pending
19 Nov 2023Editorial Decision: Revise Minor
